A Phase 3 interventional study of Entecavir and Tenofovir in Hepatitis B, Chronic, sponsored by Bristol-Myers Squibb. Completed at 67 sites in 18 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2013-11-21.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 3rd largest by enrollment of the 61 interventional ones that give a count, is one of 8 that started in 2008, is one of 13 in phase 3, and was the 8th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:
Ascentage Pharma Group Inc. · Sites in China
Ages 18+
Qing-Lei Zeng
Ages 3–6
Qing-Lei Zeng
Ages 3–6
By country, each count listing its studies:
entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 13 · Phase 4 33
First in 2001; this study’s year is marked. 8 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 629 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 109 across the 61 interventional studies. Of the 40 that completed or were terminated, 15 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 64 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 23 finished, 11 (48%) have results posted.
Among the 24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb, this one is the 2nd largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2008, is one of 11 in phase 3, and was the 8th registered.
Bristol-Myers Squibb’s Hepatitis B, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 24 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effectiveness of entecavir plus adefovir combination therapy versus entecavir monotherapy or therapy with adefovir plus lamivudine
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
With the option of adding tenofovir at week 48. (This does not apply to Korea)
Drug: Entecavir · Drug: Tenofovir
Drug: Adefovir · Drug: Lamivudine
Drug: Entecavir · Drug: Adefovir
Tablets, Oral, 1mg, once daily, 100 weeks
Also known as: Baraclude, BMS-200475
Tablets, Oral, 300 mg, once daily
Also known as: Viread
Tablets, Oral, 10mg, once daily, 100 weeks
Also known as: Hepsera
Tablets, Oral, 100mg, once daily, 100 weeks
Also known as: Epivir
Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 50 IU/mL (Approximately 300 Copies/mL) by Polymerase Chain Reaction (PCR) at Week 48
HBV DNA assessments were performed using the Roche COBAS® TaqMan High Pure System (HPS) assay. HBV DNA less than (\<)50 International units per milliliter (IU/mL) = approximately 300 copies/mL. Percentage of participants calculated n/N; n= number of participants with HBV DNA \<50 IU/mL; N = number of participants analyzed.
Time frame: Week 48
Percentage of Participants With HBV DNA < 50 IU/mL (Approximately 300 Copies/mL) by PCR at Week 96
HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. HBV DNA \< 50 IU/mL = approximately 300 copies/mL. Percentage n/N: n= number of participants with HBV DNA \<50 IU/mL; N = number of participants analyzed.
Time frame: Week 96
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48
HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Percentage n/N: n= number of participants with outcome result; N = number of participants analyzed.
Time frame: Week 48
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 96
HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Percentage n/N: n= number of participants with outcome result; N = number of participants analyzed.
Time frame: Week 96
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 48
HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOD is the lowest concentration level that can be determined to be statistically different from a blank (99% confidence). The LOD is typically determined to be in the region where the signal to noise ratio is greater than 5. Limits of detection are matrix-, method-, and analyte-specific.
Time frame: Week 48
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 96
HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOD is the lowest amount or concentration of analyte in a sample, which can be reliably detected, but not necessarily quantified.
Time frame: Week 96
Percentage of Participants With HBV DNA by PCR Category at Week 48
HBV DNA assessments were performed using the Roche COBAS® TaqMan High Pure System (HPS) assay.
Time frame: Week 48
Percentage of Participants With HBV DNA by PCR Category at Week 96
HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay.
Time frame: Week 96
Change in Mean log10 From Baseline in HBV DNA at Week 48
HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan TaqMan HPS assay. Reduction in log10 HBV count=reduced viral load, negative values means reduction.
Time frame: Baseline, Week 48
Change in Mean log10 From Baseline in HBV DNA at Week 96
HBV DNA was analyzed by PCR, using the Roche COBAS® TaqMan HPS assay. Reduction in log10 HBV count=reduced viral load.
Time frame: Baseline, Week 96
Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 48
ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 or 48 U/L.
Time frame: Week 48
Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 96
ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 U/L.
Time frame: Baseline, Week 96
Percentage of Participants With Confirmed HBeAg Loss at Week 48 (Treated HBeAg Positive Participants Only)
HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week
Time frame: Week 48
Percentage of Participants With Confirmed HBeAg Loss at Week 96 (Treated HBeAg Positive Participants Only)
HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week
Time frame: Week 96
Percentage of Participants With HBeAg Seroconversion at Week 48 (Treated HBeAg-positive Participants Only)
HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).
Time frame: Week 48
Percentage of Participants With HBeAg Seroconversion at Week 96 (Treated HBeAg-positive Participants Only)
HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).
Time frame: Week 96
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.
Time frame: Week 48
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 96
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.
Time frame: Week 96
Percentage of Participants With HBsAg Seroconversion at Week 48
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.
Time frame: Week 48
Percentage of Participants With HBsAg Seroconversion at Week 96
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.
Time frame: Week 96
Cumulative Probability of Emergent Genotypic Resistance at Year 1
yr=year. Cumulative probability (CP): Ptotal=1-(1-Pyr1)\*(1-Pyr2) where Pyear(i)= number of participants with events at Year i divided by number of participants at risk at Year i for i = 1,2. An "event" is defined as resistance or resistance with virologic breakthrough in a yearly interval. Participants 'at risk' are those who were treated during Year i and did not develop that resistance or resistance with virologic breakthrough prior to Year i. CP were calculated separately for ETV, ADV and TDF resistance. Participants who discontinue from study drug in Year i were assumed to be in follow up for the entire year. (VBT; a ≥ 1 log10 increase in HBV DNA from the on-treatment nadir, confirmed by 2 sequential HBV DNA results or observed at the last on-treatment HBV DNA). ETVr = ETV resistance (rtM204V/I/S plus any substitution at rtT184, rtS202, or rtM250); ADVr/TDFr = ADV/TDF resistance (rtA181T/V or rtN236T = ADVr and TDFr, rtA194T = TDFr only).
Time frame: Year 1
Cumulative Probability of Emergent Genotypic Resistance at Year 2
Cumulative probability (CP): Ptotal=1-(1-Pyr1)\*(1-Pyr2) where Pyear(i)= number of participants with events at Year i divided by number of participants at risk at Year i for i = 1,2. An "event" is defined as resistance or resistance with virologic breakthrough in a yearly interval. Participants 'at risk' are those who were treated during Year i and did not develop that resistance or resistance with virologic breakthrough prior to Year i. CP were calculated separately for ETV, ADV and TDF resistance. Participants who discontinue from study drug in Year i were assumed to be in follow up for the entire year. (VBT; a ≥ 1 log10 increase in HBV DNA from the on-treatment nadir, confirmed by 2 sequential HBV DNA results or observed at the last on-treatment HBV DNA). ETVr = ETV resistance (rtM204V/I/S plus any substitution at rtT184, rtS202, or rtM250); ADVr/TDFr = ADV/TDF resistance (rtA181T/V or rtN236T = ADVr and TDFr, rtA194T = TDFr only).
Time frame: Year 2
Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to Adverse Events or Laboratory Abnormalities During Treatment
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. Grade 1 = mild, Grade 2= moderate, Grade 3 = severe, Grade 4 = life threatening/disabling, Grade 5 = death.
Time frame: From start of study therapy through Week 100 + 5 days
Number of Participants With Laboratory Abnormalities: Hematology
Criteria for hematology abnormalities were: Hemoglobin: \<=11.0 g/dL; White Blood Cells: \<4000/mm\^3; Absolute Neutrophils (includes absolute bands): \<1500/mm\^3; Platelets: \<=99,000/mm\^3; International Normalized Ratio: ≥ 1.5 and ≥ 0.5 from baseline.
Time frame: From start of study through Week 100 + 5 days
Number of Participants With Laboratory Abnormalities: Serum Chemistry
ULN=upper limit of normal (Normal ranges are Central lab data and vary according to the site). ALT:\>1.25\*ULN, AST:\>1.25\*ULN, ALP:\>1.25\*ULN, Total Bilirubin:\>1.1\*ULN, Serum Lipase:\>1.10\*ULN, Creatinine:\>1.1\*ULN, Blood Urea Nitrogen:1.25\*ULN, Hyperglycemia:\>116 mg/dL, Hypoglycemia:\<64 mg/dL, Hyponatremia:\<132meq/L, Hypokalemia:\<3.4 meq/L, Albumin:≥1g/dL decrease from baseline, \<3 g/dL; Hypernatremia:\>148 meq/L, Hyperkalemia:\>5.6 meq/L, Hypokalemia:\<3.4 meq/L, Hyperchloremia:\>113 meq/L, Hypochloremia:\<93 meq/L; ALT flare: on treatment (OT), \>2\*Baseline and \>10\*ULN; off treatment (OF), 2\*end of dosing value and \>10\*ULN
Time frame: On treatment : Day 1 through Week 100 + 5 days; Offtreatment = End of OT period through 24 weeks
A total of 629 participants were enrolled at 60 sites.
| Milestone | Entecavir + Adefovir (ETV+ADV) Combination Therapy | Entecavir (ETV) Monotherapy | Adefovir + Lamivudine (ADV+LVD) Combination Therapy |
|---|---|---|---|
| Started | 138 | 140 | 137 |
| Discontinued prior to week 48 visit | 4 | 2 | 2 |
| Discontinued at or after week 48 visit | 2 | 6 | 3 |
| Completed | 63 | 61 | 66 |
| Not completed | 75 | 79 | 71 |
| Withdrew: Continuing treatment | 69 | 71 | 66 |
| Withdrew: Adverse event | 1 | 3 | 2 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
| Withdrew: Lack of efficacy | 1 | 4 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 1 |
| Withdrew: Other reason | 0 | 0 | 1 |
| Milestone | Entecavir + Adefovir (ETV+ADV) Combination Therapy | Entecavir (ETV) Monotherapy | Adefovir + Lamivudine (ADV+LVD) Combination Therapy |
|---|---|---|---|
| Started | 15 | 8 | 14 |
| Completed | 1 | 0 | 2 |
| Not completed | 14 | 8 | 12 |
| Withdrew: Continuing off-treatment follow up | 10 | 8 | 11 |
| Withdrew: Follow up not required per protocol | 3 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
HBV DNA assessments were performed using the Roche COBAS® TaqMan High Pure System (HPS) assay. HBV DNA less than (\<)50 International units per milliliter (IU/mL) = approximately 300 copies/mL. Percentage of participants calculated n/N; n= number of participants with HBV DNA \<50 IU/mL; N = number of participants analyzed.
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 50 IU/mL (Approximately 300 Copies/mL) by Polymerase Chain Reaction (PCR) at Week 48 | 25.4 | 16.4 | 19.7 |
HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. HBV DNA \< 50 IU/mL = approximately 300 copies/mL. Percentage n/N: n= number of participants with HBV DNA \<50 IU/mL; N = number of participants analyzed.
| Percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Percentage of Participants With HBV DNA < 50 IU/mL (Approximately 300 Copies/mL) by PCR at Week 96 | 43.5 | 39.3 | 28.5 |
HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Percentage n/N: n= number of participants with outcome result; N = number of participants analyzed.
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48 | 25.4 | 13.6 | 16.8 |
HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection. Percentage n/N: n= number of participants with outcome result; N = number of participants analyzed.
| Percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 96 | 38.4 | 36.4 | 25.5 |
HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOD is the lowest concentration level that can be determined to be statistically different from a blank (99% confidence). The LOD is typically determined to be in the region where the signal to noise ratio is greater than 5. Limits of detection are matrix-, method-, and analyte-specific.
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 48 | 20.3 | 11.4 | 11.7 |
HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay. LOD is the lowest amount or concentration of analyte in a sample, which can be reliably detected, but not necessarily quantified.
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 96 | 33.3 | 27.1 | 20.4 |
HBV DNA assessments were performed using the Roche COBAS® TaqMan High Pure System (HPS) assay.
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| < LOQ (29 IU/mL) | 25.4 | 13.6 | 16.8 |
| LOQ to < 50 | 0 | 2.9 | 2.9 |
| 50 to < 172 | 8.0 | 2.9 | 5.8 |
| 172 to < 1,720 | 26.1 | 7.9 | 12.4 |
| 1,720 to < 17,200 | 28.3 | 22.1 | 31.4 |
| 17,200 to < 172,000 | 8.0 | 25.7 | 24.8 |
| >= 172,000 | 0.7 | 23.6 | 4.4 |
| Missing | 3.6 | 1.4 | 1.5 |
HBV DNA assessments were performed using the Roche COBAS® TaqMan HPS assay.
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| < LOQ (29 IU/mL) | 38.4 | 36.4 | 25.5 |
| LOQ to < 50 | 5.1 | 2.9 | 2.9 |
| 50 to < 172 | 10.1 | 3.6 | 5.8 |
| 172 to < 1,720 | 15.2 | 6.4 | 18.2 |
| 1,720 to < 17,200 | 20.3 | 10.0 | 24.8 |
| 17,200 to < 172,000 | 5.8 | 15.7 | 13.9 |
| >= 172,000 | 0 | 16.4 | 2.9 |
| Missing | 5.1 | 8.6 | 5.8 |
HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan TaqMan HPS assay. Reduction in log10 HBV count=reduced viral load, negative values means reduction.
| log10 (IU/mL | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| HBV DNA at Week 48 | 2.79 ± 0.093 | 4.01 ± 0.128 | 3.36 ± 0.111 |
| Change from baseline | -4.65 ± 0.077 | -3.35 ± 0.117 | -4.11 ± 0.108 |
HBV DNA was analyzed by PCR, using the Roche COBAS® TaqMan HPS assay. Reduction in log10 HBV count=reduced viral load.
| participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Change in Mean log10 From Baseline in HBV DNA at Week 96 | -5.06 ± 0.090 | -4.17 ± 0.163 | -4.49 ± 0.116 |
ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 or 48 U/L.
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 48 | 75.6 | 78.0 | 76.8 |
ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 U/L.
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 96 | 76.9 | 74.4 | 79.7 |
HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Percentage of Participants With Confirmed HBeAg Loss at Week 48 (Treated HBeAg Positive Participants Only) | 7.2 | 6.5 | 5.9 |
HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Percentage of Participants With Confirmed HBeAg Loss at Week 96 (Treated HBeAg Positive Participants Only) | 12.3 | 10.7 | 13.9 |
HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Percentage of Participants With HBeAg Seroconversion at Week 48 (Treated HBeAg-positive Participants Only) | 5.1 | 2.9 | 3.7 |
HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Percentage of Participants With HBeAg Seroconversion at Week 96 (Treated HBeAg-positive Participants Only) | 7.2 | 3.6 | 5.1 |
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48 | 0.7 | 0 | 0.7 |
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 96 | 0 | 0 | 0 |
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Percentage of Participants With HBsAg Seroconversion at Week 48 | 0.7 | 0 | 0 |
HBsAg = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Percentage of Participants With HBsAg Seroconversion at Week 96 | 0 | 0 | 0 |
yr=year. Cumulative probability (CP): Ptotal=1-(1-Pyr1)\*(1-Pyr2) where Pyear(i)= number of participants with events at Year i divided by number of participants at risk at Year i for i = 1,2. An "event" is defined as resistance or resistance with virologic breakthrough in a yearly interval. Participants 'at risk' are those who were treated during Year i and did not develop that resistance or resistance with virologic breakthrough prior to Year i. CP were calculated separately for ETV, ADV and TDF resistance. Participants who discontinue from study drug in Year i were assumed to be in follow up for the entire year. (VBT; a ≥ 1 log10 increase in HBV DNA from the on-treatment nadir, confirmed by 2 sequential HBV DNA results or observed at the last on-treatment HBV DNA). ETVr = ETV resistance (rtM204V/I/S plus any substitution at rtT184, rtS202, or rtM250); ADVr/TDFr = ADV/TDF resistance (rtA181T/V or rtN236T = ADVr and TDFr, rtA194T = TDFr only).
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| ETVr : n=134, 134, 134 | 0 | 3 | 0.7 |
| ADVr /TDFr : n=137, 137, 135 | 0.7 | 0.7 | 1.5 |
| ETVr or TDFr/ADVr : n=133, 132, 132 | 0.8 | 3.8 | 2.3 |
| ETVr and TDFr/ADVr : n=138, 139, 137 | 0 | 0 | 0 |
| ETVr with VBT: n=134, 134, 134 | 0 | 0.7 | 0 |
| ADVr /TDFr with VBT: n=137, 137, 135 | 0 | 0 | 0 |
| ETVr or ADVr/TDFr with VBT: n=133, 132, 132 | 0 | 0.8 | 0 |
| ETVr and ADVr/TDFr with VBT: n=138, 139, 137 | 0 | 0 | 0 |
Cumulative probability (CP): Ptotal=1-(1-Pyr1)\*(1-Pyr2) where Pyear(i)= number of participants with events at Year i divided by number of participants at risk at Year i for i = 1,2. An "event" is defined as resistance or resistance with virologic breakthrough in a yearly interval. Participants 'at risk' are those who were treated during Year i and did not develop that resistance or resistance with virologic breakthrough prior to Year i. CP were calculated separately for ETV, ADV and TDF resistance. Participants who discontinue from study drug in Year i were assumed to be in follow up for the entire year. (VBT; a ≥ 1 log10 increase in HBV DNA from the on-treatment nadir, confirmed by 2 sequential HBV DNA results or observed at the last on-treatment HBV DNA). ETVr = ETV resistance (rtM204V/I/S plus any substitution at rtT184, rtS202, or rtM250); ADVr/TDFr = ADV/TDF resistance (rtA181T/V or rtN236T = ADVr and TDFr, rtA194T = TDFr only).
| percentage of participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| ETVr : n=130, 128, 131 | 0.8 | 9.8 | 1.5 |
| ADVr/TDFr : n=132, 134, 131 | 0.7 | 1.5 | 2.2 |
| ETVr or ADVr/TDFr : n=128, 125, 127 | 1.5 | 10.7 | 3.8 |
| ETVr and ADVr/TDFr : n=134, 137, 135 | 0 | 0.7 | 0 |
| ETVr with VBT: n=130, 128, 131 | 0 | 6.2 | 0 |
| ADVr/TDFr with VBT: n=132, 134, 131 | 0 | 0.7 | 0 |
| ETVr or ADVr/TDFr with VBT: n=128, 125, 127 | 0 | 6.3 | 0 |
| ETVr and ADVr/TDFr with VBT: n=134, 137, 135 | 0 | 0.7 | 0 |
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded. Grade 1 = mild, Grade 2= moderate, Grade 3 = severe, Grade 4 = life threatening/disabling, Grade 5 = death.
| participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Deaths | 0 | 0 | 1 |
| SAEs | 11 | 17 | 12 |
| Discontinuations due to AEs | 1 | 2 | 2 |
| AEs | 101 | 109 | 92 |
| Grade 2-4 Related AEs | 2 | 12 | 1 |
| Grade 3-4 Related AEs | 5 | 7 | 9 |
Criteria for hematology abnormalities were: Hemoglobin: \<=11.0 g/dL; White Blood Cells: \<4000/mm\^3; Absolute Neutrophils (includes absolute bands): \<1500/mm\^3; Platelets: \<=99,000/mm\^3; International Normalized Ratio: ≥ 1.5 and ≥ 0.5 from baseline.
| participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Hemoglobin | 8 | 9 | 11 |
| White Blood Cells | 53 | 48 | 38 |
| Neutrophils | 14 | 17 | 15 |
| Platelets | 13 | 14 | 12 |
| International Normalized Ratio | 8 | 7 | 9 |
ULN=upper limit of normal (Normal ranges are Central lab data and vary according to the site). ALT:\>1.25\*ULN, AST:\>1.25\*ULN, ALP:\>1.25\*ULN, Total Bilirubin:\>1.1\*ULN, Serum Lipase:\>1.10\*ULN, Creatinine:\>1.1\*ULN, Blood Urea Nitrogen:1.25\*ULN, Hyperglycemia:\>116 mg/dL, Hypoglycemia:\<64 mg/dL, Hyponatremia:\<132meq/L, Hypokalemia:\<3.4 meq/L, Albumin:≥1g/dL decrease from baseline, \<3 g/dL; Hypernatremia:\>148 meq/L, Hyperkalemia:\>5.6 meq/L, Hypokalemia:\<3.4 meq/L, Hyperchloremia:\>113 meq/L, Hypochloremia:\<93 meq/L; ALT flare: on treatment (OT), \>2\*Baseline and \>10\*ULN; off treatment (OF), 2\*end of dosing value and \>10\*ULN
| participants | ETV+ADV Combination Therapy | ETV Monotherapy | ADV+LVD Combination Therapy |
|---|---|---|---|
| Alanine aminotransferase (ALT) | 76 | 83 | 74 |
| Aspartate aminotransferase (AST) | 60 | 62 | 53 |
| Alkaline Phosphatase (ALP) | 8 | 4 | 6 |
| Albumin | 1 | 1 | 1 |
| Serum Lipase | 24 | 33 | 24 |
| Creatinine | 2 | 2 | 4 |
| Blood Urea Nitrogen | 0 | 1 | 2 |
| Hyperglycemia | 39 | 46 | 37 |
| Hypoglycemia | 9 | 5 | 9 |
| Hypernatremia | 10 | 10 | 10 |
| Hyponatremia | 0 | 0 | 0 |
| Hyperkalemia | 3 | 4 | 5 |
| Hypokalemia | 4 | 2 | 2 |
| Hyperchloremia | 1 | 1 | 1 |
| Hypochloremia | 1 | 0 | 0 |
| ALT flare - Ontreatment | 3 | 2 | 2 |
| ALT flare - Offtreatment | 0 | 0 | 0 |
Collected over Up to Week 96. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ADV + LVD Combination Therapy | — | 13/137 (9.5%) | 62/137 (45.3%) |
| ETV Monotherapy | — | 21/140 (15%) | 75/140 (53.6%) |
| ETV + ADV Combination Therapy | — | 14/138 (10.1%) | 63/138 (45.7%) |
| Event | ADV + LVD Combination Therapy | ETV Monotherapy | ETV + ADV Combination Therapy |
|---|---|---|---|
| Hepatic neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/137 | 5/140 | 4/138 |
| HaemorrhoidsGastrointestinal disorders | 0/137 | 3/140 | 1/138 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/137 | 0/140 | 2/138 |
| AppendicitisInfections and infestations | 0/137 | 2/140 | 1/138 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 1/137 | 1/140 | 0/138 |
| Intracranial hypotensionNervous system disorders | 1/137 | 0/140 | 0/138 |
| MelaenaGastrointestinal disorders | 1/137 | 0/140 | 0/138 |
| DizzinessNervous system disorders | 1/137 | 0/140 | 0/138 |
| SpondylolisthesisMusculoskeletal and connective tissue disorders | 1/137 | 0/140 | 0/138 |
| Wrist fractureInjury, poisoning and procedural complications | 1/137 | 1/140 | 1/138 |
| Event | ADV + LVD Combination Therapy | ETV Monotherapy | ETV + ADV Combination Therapy |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 19/137 | 28/140 | 23/138 |
| NasopharyngitisInfections and infestations | 8/137 | 17/140 | 17/138 |
| HeadacheNervous system disorders | 13/137 | 5/140 | 8/138 |
| DyspepsiaGastrointestinal disorders | 8/137 | 6/140 | 10/138 |
| Abdominal pain upperGastrointestinal disorders | 6/137 | 10/140 | 5/138 |
| Hepatic steatosisHepatobiliary disorders | 9/137 | 8/140 | 4/138 |
| FatigueGeneral disorders | 8/137 | 4/140 | 4/138 |
| Abdominal discomfortGastrointestinal disorders | 7/137 | 3/140 | 8/138 |
| Alanine aminotransferase increasedInvestigations | 5/137 | 8/140 | 8/138 |
| NauseaGastrointestinal disorders | 4/137 | 8/140 | 6/138 |
| Age Continuous(years) | Entecavir + Adefovir (ETV+ADV) Combination Therapy | Entecavir (ETV) Monotherapy | Adefovir + Lamivudine (ADV+LVD) Combination Therapy | Total |
|---|---|---|---|---|
| Median | 46.0 (18 to 69) | 43.5 (19 to 71) | 43.0 (16 to 74) | 45.0 (16 to 74) |
| Sex: Female, Male(Participants) | Entecavir + Adefovir (ETV+ADV) Combination Therapy | Entecavir (ETV) Monotherapy | Adefovir + Lamivudine (ADV+LVD) Combination Therapy | Total |
|---|---|---|---|---|
| Female | 47 | 52 | 40 | 139 |
| Male | 91 | 88 | 97 | 276 |
| Race/Ethnicity, Customized(participants) | Entecavir + Adefovir (ETV+ADV) Combination Therapy | Entecavir (ETV) Monotherapy | Adefovir + Lamivudine (ADV+LVD) Combination Therapy | Total |
|---|---|---|---|---|
| Asian | 132 | 131 | 126 | 389 |
| White | 6 | 9 | 11 | 26 |
| Region of Enrollment(participants) | Entecavir + Adefovir (ETV+ADV) Combination Therapy | Entecavir (ETV) Monotherapy | Adefovir + Lamivudine (ADV+LVD) Combination Therapy | Total |
|---|---|---|---|---|
| Australia | 0 | 1 | 1 | 2 |
| Canada | 1 | 0 | 0 | 1 |
| Hong Kong | 5 | 7 | 5 | 17 |
| India | 4 | 3 | 5 | 12 |
| Indonesia | 0 | 1 | 0 | 1 |
| Italy | 1 | 0 | 0 | 1 |
| Korea, Republic of | 108 | 105 | 102 | 315 |
| Malaysia | 3 | 0 | 2 | 5 |
| Philippines | 0 | 1 | 1 | 2 |
| Poland | 5 | 9 | 9 | 23 |
| Russian Federation | 0 | 0 | 2 | 2 |
| Singapore | 1 | 1 | 0 | 2 |
| Taiwan | 8 | 9 | 9 | 26 |
| Thailand | 1 | 3 | 1 | 5 |
| Turkey | 1 | 0 | 0 | 1 |
| Hepatitis B surface antigen (HBsAg) status at baseline(participants) | Entecavir + Adefovir (ETV+ADV) Combination Therapy | Entecavir (ETV) Monotherapy | Adefovir + Lamivudine (ADV+LVD) Combination Therapy | Total |
|---|---|---|---|---|
| Positive | 138 | 140 | 137 | 415 |
| Negative | 0 | 0 | 0 | 0 |
| Hepatitis B e antigen (HBeAg) status at baseline(participants) | Entecavir + Adefovir (ETV+ADV) Combination Therapy | Entecavir (ETV) Monotherapy | Adefovir + Lamivudine (ADV+LVD) Combination Therapy | Total |
|---|---|---|---|---|
| Positive | 138 | 139 | 135 | 412 |
| Negative | 0 | 1 | 2 | 3 |
| Hepatitis B e antibody (HBeAb) at baseline(participants) | Entecavir + Adefovir (ETV+ADV) Combination Therapy | Entecavir (ETV) Monotherapy | Adefovir + Lamivudine (ADV+LVD) Combination Therapy | Total |
|---|---|---|---|---|
| Positive | 0 | 1 | 2 | 3 |
| Negative | 138 | 139 | 135 | 412 |
| Alanine Aminotransferase (ALT)(U/L) | Entecavir + Adefovir (ETV+ADV) Combination Therapy | Entecavir (ETV) Monotherapy | Adefovir + Lamivudine (ADV+LVD) Combination Therapy | Total |
|---|---|---|---|---|
| Median | 49 (10 to 480) | 50 (12 to 367) | 45 (14 to 1300) | 47 (10 to 1300) |
5 further baseline measures are reported on the registry.
The record gives a start of Mar 2008, a primary completion of Jan 2011 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Entecavir · Tenofovir · Adefovir · Lamivudine